Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

Malignant Mesothelioma (MM) is a rare and highly aggressive cancer that develops from mesothelial cells lining the pleura and other internal cavities, and is often associated with asbestos exposure. To date, no effective treatments have been made available for this pathology. Herein, we propose a no...

Full description

Bibliographic Details
Main Authors: Peter R. Hoffmann, Fukun W. Hoffmann, Thomas A. Premeaux, Tsuyoshi Fujita, Elisa Soprana, Maddalena Panigada, Glen M. Chew, Guilhem Richard, Pooja Hindocha, Mark Menor, Vedbar S. Khadka, Youping Deng, Lenny Moise, Lishomwa C. Ndhlovu, Antonio Siccardi, Andrew D. Weinberg, Anne S. De Groot, Pietro Bertino
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
cancer vaccines
OX40
mesothelioma
epimatrix
immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00720/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00720/full

Similar Items